Arlene Chan

18PUBLICATIONS
81CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHealth and ecological risk assessmentInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Dec 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.

Barbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro

|Apr 10, 2025
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies.

José A García-Saenz, Gonzalo Spera, Marina Pollán

|Feb 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.

Peter A Fasching, Dennis Slamon, Zbigniew Nowecki

|Dec 06, 2024
Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer.

Arlene Chan, Jespal Gill, HuiJun Chih

|Jun 22, 2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Sara M Tolaney, Arlene Chan, Katarina Petrakova

|Feb 08, 2023
Prognostic role of immune environment in luminal B early breast cancer.

Arlene Chan, Jespal Gill, HuiJun Chih

Pageof 3

Frequent Collaborators

2 joint publications

Hope S Rugo

2 joint publications

Christopher Lomma

2 joint publications

Zbigniew Nowecki

2 joint publications

Miguel Martin